Journal articles on the topic 'Third-generation aromatase inhibitor'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Third-generation aromatase inhibitor.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Lønning, Per Eystein, and Hans Petter Eikesdal. "Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved." Endocrine-Related Cancer 20, no. 4 (April 26, 2013): R183—R201. http://dx.doi.org/10.1530/erc-13-0099.
Full textYante, I. Ketut, Desak Gede Agung Suprabawati, and Iskandar Ali. "Comparison of Recurrence Rates in Patients with Locally Advanced Breast Cancer after Mastectomy and Received Aromatase Inhibitor Therapy with Steroids and Nonsteroids." Bioscientia Medicina : Journal of Biomedicine and Translational Research 5, no. 10 (June 15, 2021): 945–48. http://dx.doi.org/10.32539/bsm.v5i10.360.
Full textYante, I. Ketut, Desak Gede Agung Suprabawati, and Iskandar Ali. "Comparison of Recurrence Rates in Patients with Locally Advanced Breast Cancer after Mastectomy and Received Aromatase Inhibitor Therapy with Steroids and Nonsteroids." Bioscientia Medicina : Journal of Biomedicine and Translational Research 5, no. 4 (June 15, 2021): 882–85. http://dx.doi.org/10.32539/bsm.v5i4.360.
Full textChowdhury, Simon, and Paul A. Ellis. "Recent advances in the use of aromatase inhibitors for women postmenopausal breast cancer." British Menopause Society Journal 11, no. 3 (September 1, 2005): 96–102. http://dx.doi.org/10.1258/136218005775544408.
Full textHowell, Anthony. "Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?" Women's Health 1, no. 3 (November 2005): 309–22. http://dx.doi.org/10.2217/17455057.1.3.309.
Full textRaymond, Lendelle, Nikita Rayani, Grace Polson, Kylie Sikorski, Ailin Lian, and Melissa A. VanAlstine-Parris. "Determining the IC50 Values for Vorozole and Letrozole, on a Series of Human Liver Cytochrome P450s, to Help Determine the Binding Site of Vorozole in the Liver." Enzyme Research 2015 (November 9, 2015): 1–4. http://dx.doi.org/10.1155/2015/321820.
Full textFadeeva, Ekaterina P., Alla S. Lisyanskaya, Georgiy M. Manikhas, Ruslan I. Glushakov, and Natalia I. Tapilskaya. "Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy." Reviews on Clinical Pharmacology and Drug Therapy 14, no. 2 (June 15, 2016): 47–57. http://dx.doi.org/10.17816/rcf14247-57.
Full textde Jong, P. Chr, J. van de Ven, J. W. R. Nortier, I. Maitimu-Smeele, G. H. Denker, J. H. H. Thijssen, P. H. Th J. Slee, and M. A. Blankenstein. "Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third generation aromatase inhibitor vorozole." European Journal of Cancer 33 (September 1997): S9. http://dx.doi.org/10.1016/s0959-8049(97)84407-3.
Full textGoss, Paul E. "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor." Breast Cancer Research and Treatment 49, S1 (May 1998): S59—S65. http://dx.doi.org/10.1023/a:1006052923468.
Full textYoshizawa-Ogasawara, Atsuko, Noriyuki Katsumata, Reiko Horikawa, Mari Satoh, Tatsuhiko Urakami, and Toshiaki Tanaka. "Third-generation Aromatase Inhibitor Improved Adult Height in a Japanese Boy with Testotoxicosis." Clinical Pediatric Endocrinology 23, no. 2 (2014): 53–58. http://dx.doi.org/10.1297/cpe.23.53.
Full textAndrikopoulou, Angeliki, Oraianthi Fiste, Michalis Liontos, Meletios-Athanasios Dimopoulos, and Flora Zagouri. "Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review." Cancers 13, no. 3 (January 26, 2021): 465. http://dx.doi.org/10.3390/cancers13030465.
Full textSteele, N., J. Zekri, R. Coleman, R. Leonard, K. Dunn, A. Bowman, I. Manifold, I. Kunkler, O. Purohit, and D. Cameron. "Exemestane in metastatic breast cancer: Effective therapy after third-generation non-steroidal aromatase inhibitor failure." Breast 15, no. 3 (June 2006): 429–35. http://dx.doi.org/10.1016/j.breast.2005.08.032.
Full textWang, J., S. Jain, W. Heller, D. Mackie, V. Watson, M. Dweck, R. C. Coombes, and C. Palmieri. "Fulvestrant in advanced breast cancer following following failure of tamoxifen and a third generation aromatase inhibitor." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 1073. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1073.
Full textLigibel, Jennifer A., and Eric P. Winer. "The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer." Journal of the National Comprehensive Cancer Network 1, no. 2 (April 2003): 215–21. http://dx.doi.org/10.6004/jnccn.2003.0020.
Full textMiller, W. R., T. J. Anderson, S. White, D. Evans, A. Krause, and J. M. Dixon. "Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience." Endocrine-Related Cancer 12, Supplement_1 (July 2005): S119—S123. http://dx.doi.org/10.1677/erc.1.00995.
Full textBarros-Oliveira, Maria da Conceição, Danylo Rafhael Costa-Silva, Danielle Benigno de Andrade, Umbelina Soares Borges, Cléciton Braga Tavares, Rafael Soares Borges, Janaína de Moraes Silva, and Benedito Borges da Silva. "Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review." Revista da Associação Médica Brasileira 63, no. 4 (April 2017): 371–78. http://dx.doi.org/10.1590/1806-9282.63.04.371.
Full textGoss, Paul E., David Walde, Roland De Coster, Christine Langenaeken, and Jan Bruynseels. "Rivizor – A New Third-Generation Aromatase Inhibitor for the Treatment of Advanced Breast Cancer after Tamoxifen Failure." Oncology 56, no. 2 (1999): 114–21. http://dx.doi.org/10.1159/000011951.
Full textLefevre, Hervé, Claire Bouvattier, Najiba Lahlou, Catherine Adamsbaum, Pierre Bougnères, and Jean-Claude Carel. "Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor." European Journal of Endocrinology 154, no. 2 (February 2006): 221–27. http://dx.doi.org/10.1530/eje.1.02085.
Full textIngle, James N., Vera J. Suman, Kendrith M. Rowland, Deepu Mirchandani, Albert M. Bernath, John K. Camoriano, Paul A. S. Fishkin, Daniel A. Nikcevich, and Edith A. Perez. "Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032." Journal of Clinical Oncology 24, no. 7 (March 1, 2006): 1052–56. http://dx.doi.org/10.1200/jco.2005.04.1053.
Full textRay, Amitabha, and Monica Ficek. "Immunomodulatory effects of anti-estrogenic drugs." Acta Pharmaceutica 62, no. 2 (June 1, 2012): 141–55. http://dx.doi.org/10.2478/v10007-012-0012-3.
Full textAmaral, Cristina, Georgina Correia-da-Silva, Cristina Ferreira Almeida, Maria João Valente, Carla Varela, Elisiário Tavares-da-Silva, Anne Marie Vinggaard, Natércia Teixeira, and Fernanda M. F. Roleira. "An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER+) Breast Cancer: Effects on Sensitive and Resistant Cell Lines." Molecules 28, no. 2 (January 12, 2023): 789. http://dx.doi.org/10.3390/molecules28020789.
Full textGoss, P. E., E. P. Winer, I. F. Tannock, and L. H. Schwartz on behalf of the North Ame. "Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients." Journal of Clinical Oncology 17, no. 1 (January 1999): 52. http://dx.doi.org/10.1200/jco.1999.17.1.52.
Full textAnagha, Pooleriveetil Padikkal, and Suchandra Sen. "The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis." Journal of Oncology 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/625060.
Full textWilson, Sheridan, and Stephen K. Chia. "Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Applying the Results from Recent Clinical Trials into Daily Practice—Insights, Limitations, and Moving Forward." American Society of Clinical Oncology Educational Book, no. 33 (May 2013): e20-e27. http://dx.doi.org/10.14694/edbook_am.2013.33.e20.
Full textTurkistani, Abdullah, and Sharon Marsh. "Pharmacogenomics of third-generation aromatase inhibitors." Expert Opinion on Pharmacotherapy 13, no. 9 (May 17, 2012): 1299–307. http://dx.doi.org/10.1517/14656566.2012.687721.
Full textLONNING, P. "Pharmacokinetics of third-generation aromatase inhibitors." Seminars in Oncology 30 (August 2003): 23–32. http://dx.doi.org/10.1016/s0093-7754(03)00305-1.
Full textLytkin, D. V., A. L. Zagayko, and T. O. Briukhanova. "The effect of third-generation aromatase inhibitors on aromatase avtivity in visceral adipose tissue." Regulatory Mechanisms in Biosystems 9, no. 2 (August 13, 2018): 209–15. http://dx.doi.org/10.15421/021831.
Full textSun, Linjia, Xiaoyang Sun, Yu Chen, Binjie Wang, and Xiaohui Chen. "Degradation Kinetics Study of Anastrozole in Different Conditions by Reverse-Phase High-Performance Liquid Chromatography and Confirmation of its Major Degradation Product by Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry." Current Pharmaceutical Analysis 15, no. 3 (February 11, 2019): 217–23. http://dx.doi.org/10.2174/1573412914666180406130108.
Full textPapadimitriou, Dimitrios T., Eleni Dermitzaki, Kleanthis Kleanthous, Anastasios Papadimitriou, and George Mastorakos. "Exaggerated Premature Adrenarche in Boys: Comparative Study of a Therapeutic Intervention With the Aromatase Inhibitor Anastrozole Versus Morning Low Dose Hydrocortisone." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A666—A667. http://dx.doi.org/10.1210/jendso/bvab048.1360.
Full textLønning, Per Eystein, and Jürgen Geisler. "Indications and limitations of third-generation aromatase inhibitors." Expert Opinion on Investigational Drugs 17, no. 5 (April 30, 2008): 723–39. http://dx.doi.org/10.1517/13543784.17.5.723.
Full textMcCloskey, Eugene. "Effects of third-generation aromatase inhibitors on bone." European Journal of Cancer 42, no. 8 (May 2006): 1044–51. http://dx.doi.org/10.1016/j.ejca.2005.10.028.
Full textLenz, A. M., D. Shulman, E. A. Eugster, S. Rahhal, J. S. Fuqua, O. H. Pescovitz, and K. A. Lewis. "Bicalutamide and Third-Generation Aromatase Inhibitors in Testotoxicosis." PEDIATRICS 126, no. 3 (August 16, 2010): e728-e733. http://dx.doi.org/10.1542/peds.2010-0596.
Full textChia, Stephen, William Gradishar, Louis Mauriac, Jose Bines, Frederic Amant, Miriam Federico, Luis Fein, et al. "Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT." Journal of Clinical Oncology 26, no. 10 (April 1, 2008): 1664–70. http://dx.doi.org/10.1200/jco.2007.13.5822.
Full textLonninq, P. E. "Are there any difference between third-generation aromatase inhibitors?" European Journal of Cancer Supplements 6, no. 7 (April 2008): 52. http://dx.doi.org/10.1016/s1359-6349(08)70326-4.
Full textGoss, Paul E., and Kathrin Strasser. "Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer." Journal of Clinical Oncology 19, no. 3 (February 1, 2001): 881–94. http://dx.doi.org/10.1200/jco.2001.19.3.881.
Full textRatre, Pooja, Keerti Mishra, Amit Dubey, Amber Vyas, Akhlesh Jain, and Suresh Thareja. "Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch." Anti-Cancer Agents in Medicinal Chemistry 20, no. 17 (November 12, 2020): 1994–2004. http://dx.doi.org/10.2174/1871520620666200627204105.
Full textL√∏nning, P. E. "Aromatase inhibitors in breast cancer." Endocrine-related cancer 11, no. 2 (June 2004): 179–89. http://dx.doi.org/10.1677/erc.0.0110179.
Full textNabholtz, Jean-Marc A., and David M. Reese. "Third-generation aromatase inhibitors in the treatment of advanced breast cancer." Breast Cancer 8, no. 4 (October 2001): 305–9. http://dx.doi.org/10.1007/bf02967529.
Full textRieber, Alyssa G., and Richard L. Theriault. "Aromatase Inhibitors in Postmenopausal Breast Cancer Patients." Journal of the National Comprehensive Cancer Network 3, no. 3 (May 2005): 309–14. http://dx.doi.org/10.6004/jnccn.2005.0018.
Full textRocha-Cadman, Xiomara, Mary Jane Massie, and Katherine Du Hamel. "Aromatase inhibitors and mood disturbances." Palliative and Supportive Care 10, no. 3 (June 8, 2012): 225–27. http://dx.doi.org/10.1017/s1478951512000636.
Full textMORALES, L., D. TIMMERMAN, P. NEVEN, and R. PARIDAENS. "Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients." International Journal of Gynecological Cancer 16, s2 (September 2006): 515–17. http://dx.doi.org/10.1111/j.1525-1438.2006.00684.x.
Full textGaruti, Giancarlo, Fulvia Cellani, Giovanna Centinaio, Giuseppe Montanari, Giulio Nalli, and Massimo Luerti. "Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors." Gynecologic Oncology 103, no. 2 (November 2006): 599–603. http://dx.doi.org/10.1016/j.ygyno.2006.04.004.
Full textAugusto, Tiago, Cristina Amaral, Natércia Teixeira, and Georgina Correia-da-Silva. "The involvement of autophagy in the acquired resistance to third-generation aromatase inhibitors." Free Radical Biology and Medicine 120 (May 2018): S118. http://dx.doi.org/10.1016/j.freeradbiomed.2018.04.388.
Full textSimsa, Peter, Attila Mihalyi, Cleophas M. Kyama, Jason M. Mwenda, Vilmos Fülöp, and Thomas M. D'Hooghe. "Selective Estrogen-Receptor Modulators and Aromatase Inhibitors: Promising New Medical Therapies for Endometriosis?" Women's Health 3, no. 5 (September 2007): 617–28. http://dx.doi.org/10.2217/17455057.3.5.617.
Full textDamodaran, Senthil, Paul V. Plourde, Halle C. F. Moore, Ian Churchill Anderson, and David Jay Portman. "Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 1022. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1022.
Full textBonte, J. "Third generation aromatase inhibitors and inactivators in the treatment and prevention of breast cancer." European Journal of Cancer 36 (September 2000): 114. http://dx.doi.org/10.1016/s0959-8049(00)00269-0.
Full textBorne, J. "Second and third generation aromatase inhibitors in the treatment and chemoprevention of breast cancer." International Journal of Gynecology & Obstetrics 70 (2000): A10. http://dx.doi.org/10.1016/s0020-7292(00)81965-7.
Full textKhan, Qamar J., Anne P. O'Dea, and Priyanka Sharma. "Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors." Journal of Oncology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/654348.
Full textAugusto, Tiago Vieira, Georgina Correia-da-Silva, Cecília M. P. Rodrigues, Natércia Teixeira, and Cristina Amaral. "Acquired resistance to aromatase inhibitors: where we stand!" Endocrine-Related Cancer 25, no. 5 (May 2018): R283—R301. http://dx.doi.org/10.1530/erc-17-0425.
Full textVan Asten, Kathleen, Patrick Neven, Anneleen Lintermans, Hans Wildiers, and Robert Paridaens. "Aromatase inhibitors in the breast cancer clinic: focus on exemestane." Endocrine-Related Cancer 21, no. 1 (February 2014): R31—R49. http://dx.doi.org/10.1530/erc-13-0269.
Full text